---
document_datetime: 2026-02-17 13:46:59
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/inflectra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: inflectra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.2689156
conversion_datetime: 2026-02-21 13:08:46.686009
docling_version:
  docling-serve: 1.13.0
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
## Inflectra

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I.11 Introduction of, or change(s) to, the | 16/02/2026                          |                                             |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000323223                     | obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z - to update the RMP for Inflectra. The update ensures alignment with the latest RMP (version 18.0 dated 30 September 2025) submitted by Celltrion for Remsima, as part of the closing sequence for procedure EMEA/H/C/002576/X/0149.                                                                                                                                                                                                                                                                                                |            |             |                                                                                                                                                                                                                                                                                                                                                                 |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000294606 | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a (Type IB) - To update Sections 2, 4.4, and 6.1 of the SmPC and Sections 2 and 6 of the PL with information on the excipient polysorbate 80, in accordance with the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use' and aligned with approved changes to the reference product Remicade. | 10/09/2025 | SmPC and PL | To update Sections 2, 4.4, and 6.1 of the SmPC and Sections 2 and 6 of the PL with information on the excipient polysorbate 80, in accordance with the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use' and aligned with approved changes to the reference product Remicade. |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000269305   | 27/05/2025   | SmPC and PL   | To update sections 4.4 and 4.8 of the SmPC in order to add post-procedural complications (including infectious and non-infections complications) to the list of adverse drug reactions (ADRs) with frequency not known and update treatment recommendations for patients with a planned surgical procedure based on a cumulative review of literature, clinical trial and registry data. The Package Leaflet is updated accordingly. The change follows assessment of the same change the reference product, Remicade.   |
|-----------------------------------------|--------------|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|